ADPT

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Retrieved on: 
金曜日, 5月 31, 2024
NGS, ADPT, Patient, Progression-free survival, Bone marrow, Chronic lymphocytic leukemia, University, Clinical trial, PFS, Drug development, Safety, CLL, MRD, Blood, EHA, ALL, Multiple myeloma, ASCO, Acute lymphoblastic leukemia, Genetics, Kinetics, Society, European Hematology Association, Annual general meeting

The clinical trial data and real-world evidence to be presented at ASCO and EHA further underscore the clinical benefit of specific and sensitive MRD assessment with clonoSEQ.

Key Points: 
  • The clinical trial data and real-world evidence to be presented at ASCO and EHA further underscore the clinical benefit of specific and sensitive MRD assessment with clonoSEQ.
  • These data support the potential for a less invasive method to monitor MRD and track a patient’s response to therapy in ALL.
  • In patients with chronic lymphocytic leukemia (CLL), data from clinical trials highlighted the use of clonoSEQ to support individualized MRD-guided treatment modification.
  • clonoSEQ-related data to be presented at both ASCO and EHA:

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
水曜日, 5月 29, 2024
ADPT, Interest, Conference, Genetics

SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.

Key Points: 
  • SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
  • Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, June 11th at 10:20 a.m. Pacific Time / 1:20 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
Genetics, Multiple myeloma, MRD, ODAC, Patient, ADPT, Adaptation, Multiple sclerosis, Interest, Video game

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.
  • The MRD business, which contributed 78% of revenue, grew 52% versus the first quarter of 2023.
    clonoSEQ test volume in the first quarter of 2024 grew 41% to 17,040 tests delivered versus the first quarter of 2023.
  • Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its first quarter 2024 financial results after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time.

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
水曜日, 4月 17, 2024
Genetics, ADPT, Webcast

SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024.

Key Points: 
  • SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024.
  • Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com .
  • The webcast will be archived and available for replay within 24 hours after the event.

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Retrieved on: 
火曜日, 4月 2, 2024
MRD, Adaptation, Interim, Genetics, Investment, ADPT, CFO, Management

Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.

Key Points: 
  • Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.
  • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
  • MRD revenue of approximately $31 to $32 million for the first quarter of 2024, an increase of approximately 47% compared to the first quarter of 2023.
  • Adaptive Biotechnologies announced that Tycho Peterson, chief financial officer (CFO), will be departing the company to pursue another opportunity.

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Retrieved on: 
水曜日, 3月 27, 2024
Genetics, Webcast, ADPT

SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business update conference call and webcast after market close on Tuesday, April 2, 2024 beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Key Points: 
  • SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business update conference call and webcast after market close on Tuesday, April 2, 2024 beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com .
  • The webcast will be archived and available for replay within 24 hours after the event.

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
木曜日, 2月 22, 2024
Interest, ADPT, Genetics, Conference

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

Key Points: 
  • SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.
  • Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 2月 14, 2024
ADPT, GNE, Growth, EHR, Flatiron, Genetics, Interest, Patient, MRD, IM, IND, Workflow, Cancer, Partnership, Video game

clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.

Key Points: 
  • clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.
  • Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year.
  • Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2023 financial results after market close on Wednesday, February 14, 2024 at 4:30 PM Eastern Time.

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Retrieved on: 
月曜日, 1月 29, 2024
ADPT, Genetics, Webcast

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024.

Key Points: 
  • SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024.
  • Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com .
  • The webcast will be archived and available for replay within 24 hours after the event.

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
水曜日, 12月 27, 2023
Conference, ADPT, Genetics, Interest

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Key Points: 
  • SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
  • Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 9th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .